TY - JOUR
T1 - Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain
T2 - Relevance to Alzheimer's disease therapeutics
AU - Cao, Guoqing
AU - Bales, Kelly R.
AU - DeMattos, Ronald B.
AU - Paul, Steven M.
PY - 2007/4
Y1 - 2007/4
N2 - Liver X receptors (LXRα and LXRβ) are oxysterol receptors that function as master transcription factors mediating cholesterol homeostasis in the periphery. LXRs regulate the levels of the ABCA1 and ABCG1 cholesterol transporters as well as apolipoproteins (apoE and apoC) in various cells thereby affecting cholesterol transport and metabolism. In the brain, LXRs regulate ABCA1 in both neurons and glia resulting in cholesterol efflux from these cells. In addition, the expression of apolipoprotein E (apoE), synthesized primarily by astrocytes and microglia, is also upregulated by LXR agonists. As both apoE and the ABCA1 transporter are intimately involved in amyloid-β peptide (Aβ) transport and clearance, activation of these genes by LXR agonists in brain may have a significant impact on Aβ deposition and amyloid/ neuritic plaque formation. Furthermore, LXR activation has been shown to have significant anti-inflammatory properties. Taken together, these findings suggest that brain-penetrable LXR agonists or modulators may be useful therapeutic agents for the treatment and (or) prevention of Alzheimer's disease.
AB - Liver X receptors (LXRα and LXRβ) are oxysterol receptors that function as master transcription factors mediating cholesterol homeostasis in the periphery. LXRs regulate the levels of the ABCA1 and ABCG1 cholesterol transporters as well as apolipoproteins (apoE and apoC) in various cells thereby affecting cholesterol transport and metabolism. In the brain, LXRs regulate ABCA1 in both neurons and glia resulting in cholesterol efflux from these cells. In addition, the expression of apolipoprotein E (apoE), synthesized primarily by astrocytes and microglia, is also upregulated by LXR agonists. As both apoE and the ABCA1 transporter are intimately involved in amyloid-β peptide (Aβ) transport and clearance, activation of these genes by LXR agonists in brain may have a significant impact on Aβ deposition and amyloid/ neuritic plaque formation. Furthermore, LXR activation has been shown to have significant anti-inflammatory properties. Taken together, these findings suggest that brain-penetrable LXR agonists or modulators may be useful therapeutic agents for the treatment and (or) prevention of Alzheimer's disease.
KW - ABCA1
KW - Amyloid
KW - Apolipoprotein E
KW - Cholesterol
KW - Glia
KW - Nuclear hormone receptors
UR - http://www.scopus.com/inward/record.url?scp=34147131740&partnerID=8YFLogxK
U2 - 10.2174/156720507780362173
DO - 10.2174/156720507780362173
M3 - Review article
C2 - 17430244
AN - SCOPUS:34147131740
SN - 1567-2050
VL - 4
SP - 179
EP - 184
JO - Current Alzheimer Research
JF - Current Alzheimer Research
IS - 2
ER -